---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-23-000003"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:29:08.416873+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pacira BioSciences reports preliminary 2022 revenue of $666.8M, up 23.1% YoY

## Summary
- EXPAREL net sales $536.9M in 2022 vs $506.5M in 2021; Q4 2022 sales $138.0M, roughly flat vs prior Q4.
- ZILRETTA net sales $105.5M in 2022 vs $12.7M in 2021 (acquired Nov 2021); Q4 2022 sales $28.0M.
- Adjusted EPS expected at least $2.50 for 2022, marking ninth consecutive year of positive adjusted earnings.
- Prepaid $50M on Term Loan B in Dec 2022; plans another significant prepayment in 2023.
- Management cites strong balance sheet, durable cash flows, and outperformance vs surgical market.

## SEC filing metadata
- accession: 0001396814-23-000003
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000003/0001396814-23-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000003/pcrx-20230105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-23-000003
- JSON: https://secwatch.observer/filing/0001396814-23-000003.json
- Plain text: https://secwatch.observer/filing/0001396814-23-000003.txt

## Key facts
- Earnings Releases
  Pacira BioSciences, Inc. reported 2022 results: EPS adjusted earnings per share of at least $2.50.
  - Period: 2022
  - EPS: adjusted earnings per share of at least $2.50
  - Result: preliminary results
  source text: Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $666.8 million for 2022, compared with $541.5 million for 2021, representing an increase of 23.1 percent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000003/0001396814-23-000003-index.htm
- Earnings Releases
  Pacira BioSciences, Inc. reported 2022 results: EPS adjusted earnings per share of at least $2.50.
  - Period: 2022
  - EPS: adjusted earnings per share of at least $2.50
  - Result: preliminary results
  source text: We ended the year with a strong balance sheet and expect to report adjusted earnings per share of at least $2.50 for 2022, marking our ninth consecutive year of positive adjusted earnings.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000003/0001396814-23-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.